Phathom Pharmaceuticals, Inc. (PHAT) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
| Previous Close | 10.69 |
| Open | 10.88 |
| Day High | 11.16 |
| Day Low | 10.75 |
| 52-Week High | 18.31 |
| 52-Week Low | 7.61 |
| Volume | 592,762 |
| Average Volume | 1.19M |
| Market Cap | 866.15M |
| PE | -5.2 |
| EPS | -2.09 |
| Moving Average 50 Days | 11.47 |
| Moving Average 200 Days | 12.76 |
| Change | 0.17 |
Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on Thursday, February 26, 2026
GlobeNewswire Inc.
Feb 17, 2026 1:00 PM GMT
Management to host conference call on Thursday, February 26, 2026, at 8:00 am ESTFLORHAM PARK, N.J., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializi
Phathom Pharmaceuticals to Present at the Guggenheim Emerging Outlook Biotech Summit 2026
GlobeNewswire Inc.
Feb 05, 2026 1:00 PM GMT
FLORHAM PARK, N.J., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today that memb
Phathom Pharmaceuticals Announces Pricing of $130 Million Public Offering of Common Stock and Pre-Funded Warrants
GlobeNewswire Inc.
Jan 08, 2026 3:33 AM GMT
FLORHAM PARK, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today the prici